BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC (“Oxford”). The new credit facility will replace Vera’s existing $50 million credit facility. The initial fund ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?Moderna (NASDAQ: MRNA ) shares are down over 35% year-to-date, over 80% on a one-year basis, and since reaching their pandemic era high of over $450 per share, they are down 94%.The group is for both novice and expe ...

Company Overview - Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines to combat serious diseases [3] - The company has a broad and deep pipeline aimed at treating cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [3] - Amgen has been recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes in 2024 [4] Upcoming Events - Amgen will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20 a.m. ET [1] - The presentation will be made by Peter Griffith, CFO, and Murdo Gordon, EVP of Global Commercial Operations [1] - The webcast of the presentation will be available for replay for at least 90 days after the event [2]

Core Insights - XOMA Royalty Corporation has acquired future royalty and milestone interests in mezagitamab from BioInvent for a total of USD $30 million, with an initial payment of USD $20 million at closing [1][2] - The acquisition enhances XOMA Royalty's late-stage royalty portfolio and provides BioInvent with non-dilutive capital to advance its clinical pipeline [2] - XOMA Royalty will be entitled to additional milestones of up to USD $16.25 million and mid-single digit royalties on future commercial sales of mezagitamab [3] Company Overview - XOMA Royalty Corporation is a biotechnology royalty aggregator that helps biotech companies by acquiring potential future economics associated with therapeutic candidates [5] - BioInvent International AB focuses on discovering and developing novel immune-modulatory antibodies for cancer therapy, currently having five drug candidates in clinical trials [6] Transaction Details - The economic interest in mezagitamab originated from a 2003 cross-licensing agreement between XOMA Royalty and BioInvent [2] - An additional payment of USD $10 million will be made upon mezagitamab achieving a specific regulatory milestone related to FDA marketing approval for IgA nephropathy [2] Clinical Development - Takeda, the developer of mezagitamab, has initiated a Phase 3 clinical trial for the treatment of immune thrombocytopenia (ITP) [4] - Mezagitamab is a fully human IgG1 monoclonal antibody targeting CD38, which has the potential to be a best-in-class anti-CD38 mAb [4]

Market Overview - The recent market correction appears significant on a year-to-date chart but is expected to look less daunting over a decade, as bull markets typically last longer than downturns, leading to strong returns for most stocks over the long term [1] E-commerce Industry - E-commerce is projected to continue its growth, with only 16.2% of retail transactions in the U.S. being online as of the first quarter, indicating substantial room for growth [5] - Shopify is positioned to benefit from this trend as it enables merchants to create online storefronts, which is essential for success in the digital age [4][6] Shopify - Shopify has established itself as an innovator in the e-commerce market, offering a comprehensive suite of services including marketing, payment processing, and inventory management, which allows business owners to focus on other aspects of their operations [6] - The company has a competitive advantage due to high switching costs, which is crucial for long-term performance, although it is not consistently profitable and faces stiff competition [7] - Shopify has captured over 12% of the U.S. e-commerce market by gross merchandise volume and is expected to perform well in the next decade, especially after strategic changes that have brought it closer to profitability [8][9] Vertex Pharmaceuticals - Vertex Pharmaceuticals is a leading biotech company that has faced challenges, including disappointing phase 2 results for a drug and poor first-quarter results, but its long-term outlook remains attractive [10][11] - The company has a strong position in the cystic fibrosis market, being the only provider of medicines that address the underlying causes of the disease, which continues to drive top-line growth [11] - Vertex is expanding its product lineup with recent approvals for new medicines and has several other drugs in development, including a potential approval for a type 1 diabetes program by next year [14] - Despite recent performance issues, Vertex is considered a strong buy at current levels, with expectations for significant returns through 2035 [15]

Core Viewpoint - Renovaro Inc. has initiated legal action against Predictive Oncology Inc. to enforce a merger agreement, alleging breaches of contract and seeking specific performance and damages [1][4]. Group 1: Legal Proceedings - Renovaro filed a lawsuit on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology to enforce a merger agreement executed on January 1, 2025 [1]. - The court has ruled to expedite the trial for this lawsuit, which is pending under Case No. 2025-0509 [4]. - Renovaro claims that Predictive Oncology breached the agreement by conducting a public offering of $545,000 in securities on February 19, 2025, and later attempted to unilaterally terminate the agreement on April 3, 2025 [3]. Group 2: Financial Impact - Following the public disclosure of the merger agreement on January 6, 2025, Predictive Oncology's stock price increased by over 50% [2]. - The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches, indicating potential financial implications for both companies [4]. Group 3: Company Background - Renovaro Inc. focuses on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, aiming to accelerate precision and personalized medicine [5]. - The company includes subsidiaries such as RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, leveraging AI for diagnostics and drug development [5].

Core Viewpoint - Renovaro Inc. has initiated legal action against Predictive Oncology Inc. to enforce a merger agreement, alleging breaches of contract and seeking specific performance and damages [1][4]. Group 1: Legal Proceedings - Renovaro filed a lawsuit on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology to enforce a merger agreement executed on January 1, 2025 [1]. - The court has ruled to expedite the trial for this lawsuit, which is pending under Case No. 2025-0509 [4]. - Renovaro claims that Predictive Oncology breached the agreement by conducting a public offering of $545,000 in securities on February 19, 2025, and later attempted to unilaterally terminate the agreement [3]. Group 2: Financial Impact - Following the public disclosure of the merger agreement on January 6, 2025, Predictive Oncology's stock price increased by over 50% [2]. - The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches, indicating potential financial implications for both companies [4]. Group 3: Company Background - Renovaro Inc. focuses on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, aiming to accelerate precision and personalized medicine [5]. - The company includes subsidiaries such as RenovaroBio, which specializes in advanced cell-gene immunotherapy, and RenovaroCube, leveraging AI for diagnostics and drug development [5].

SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company’s silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addre ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - InSilico Medicine is pursuing an IPO in Hong Kong after multiple failed attempts, with a significant accumulated loss of $591 million from 2021 to 2024, raising concerns about its long-term viability and business model [1][4][5]. Financial Performance - The company reported revenues of $4.713 million, $30.147 million, $51.18 million, and $85.834 million from 2021 to 2024, respectively, with net losses of $131 million, $222 million, $212 million, and $17.096 million during the same period [5][6]. - The projected revenue for 2024 shows a growth of 92% compared to 2022, with a significant reduction in net loss by 92% [6][7]. Business Model and Operations - InSilico Medicine's core business model focuses on AI-driven drug discovery and pipeline drug development, with 92.9% of its 2024 revenue coming from this segment [7][8]. - The company has 15 candidate drugs in its pipeline, primarily in fibrosis, oncology, and immunology, but has yet to achieve commercialization [7][8]. Funding and Future Plans - The IPO proceeds are intended for further clinical development of key drug candidates, development of new AI models, and operational funding [4][5]. - The company completed a $100 million Series E financing round, increasing its valuation from $894.7 million to $1.3305 billion, reflecting a 48.71% increase over two and a half years [8].